Alyeska reports 6.24% Immunic warrant stake

Rhea-AI Filing Summary

Alyeska Investment Group and affiliates reported a 6.24% beneficial ownership stake in Immunic, Inc. common stock on a Schedule 13G/A. They report beneficial ownership of 7,500,000 shares, all through derivative securities rather than currently outstanding stock.

The reporting persons hold pre-funded warrants to purchase 3,750,000 shares of Immunic common stock and additional warrants to purchase 3,750,000 shares. The 6.24% figure is based on 120,284,724 Immunic shares outstanding, as disclosed in Immunic’s Form 10-Q filed on November 13, 2025.

Alyeska Investment Group, L.P., Alyeska Fund GP, LLC and individual reporting person Anand Parekh share voting and dispositive power over these 7,500,000 warrant-based shares and report no sole voting or dispositive power. They certify the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Immunic.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake in Immunic (IMUX) did Alyeska report on this Schedule 13G/A?

Alyeska and related reporting persons disclosed beneficial ownership of 7,500,000 shares of Immunic common stock, representing 6.24% of the class, based on 120,284,724 shares outstanding as cited from Immunic’s November 13, 2025 Form 10-Q.

How is Alyeska’s 7,500,000-share beneficial stake in Immunic (IMUX) structured?

The beneficial stake is entirely through warrants, not currently held common stock. The reporting persons hold pre-funded warrants for 3,750,000 shares and additional warrants for 3,750,000 shares of Immunic common stock, giving them the 7,500,000-share beneficial position.

What voting and dispositive powers did Alyeska report over Immunic (IMUX) shares?

The filing states no sole voting or dispositive power over Immunic shares. Instead, Alyeska and the other reporting persons have shared voting power and shared dispositive power over 7,500,000 shares, all tied to the reported warrants.

On what share count is Alyeska’s 6.24% Immunic (IMUX) ownership based?

The 6.24% beneficial ownership is calculated assuming 120,284,724 Immunic common shares outstanding. This outstanding share figure comes from Immunic’s Form 10-Q filed on November 13, 2025, which the reporting persons cite explicitly.

Did Alyeska indicate any intent to influence control of Immunic (IMUX)?

No. The reporting persons certify the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Immunic, nor in connection with any transaction having that purpose or effect.

Who are the reporting persons on the Immunic (IMUX) Schedule 13G/A filing?

The Schedule 13G/A lists three reporting persons: Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh. All three report the same 7,500,000-share beneficial ownership with shared voting and dispositive power over the Immunic warrants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 04:41 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Immunic, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

4525EP101

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 4525EP101

1

Names of Reporting Persons

Alyeska Investment Group, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,500,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,500,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,500,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.24 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 4525EP101

1

Names of Reporting Persons

Alyeska Fund GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,500,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,500,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,500,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.24 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 4525EP101

1

Names of Reporting Persons

Anand Parekh

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,500,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,500,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,500,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.24 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Immunic, Inc.
(b)	Address of issuer's principal executive offices: 1200 Avenue of the Americas, Suite 200, New York, NY 10036
Item 2.
(a)	Name of person filing: (i) Alyeska Investment Group, L.P. (ii) Alyeska Fund GP, LLC (iii) Anand Parekh
(b)	Address or principal business office or, if none, residence: (i) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601 (ii) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601 (iii) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601
(c)	Citizenship: (i) Alyeska Investment Group, L.P. - Delaware (ii) Alyeska Fund GP, LLC - Delaware (iii) Anand Parekh - United States of America
(d)	Title of class of securities: Common Stock, $0.0001 par value
(e)	CUSIP No.: 4525EP101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 7,500,000
(b)	Percent of class: 6.24%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 7,500,000
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 7,500,000
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Alyeska Investment Group, L.P.

Signature:	Jason Bragg
Name/Title:	Jason Bragg | Chief Financial Officer
Date:	02/17/2026

Alyeska Fund GP, LLC

Signature:	Jason Bragg
Name/Title:	Jason Bragg | Chief Financial Officer
Date:	02/17/2026

Anand Parekh

Signature:	Anand Parekh
Name/Title:	Anand Parekh | Self
Date:	02/17/2026

Exhibit Information

The reporting persons hold pre-funded warrants to purchase 3,750,000 shares of the Issuer's Common Stock and hold warrants to purchase 3,750,000 shares of the Issuer's Common Stock (the "Warrants"). The percentage calculation assumes that there are currently 120,284,724 outstanding Common Stock of the Issuer, based on the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 13, 2025. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.